Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Mar;25(3):377–379. doi: 10.1128/aac.25.3.377

In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.

D J Pohlod, L D Saravolatz
PMCID: PMC185523  PMID: 6326666

Abstract

The in vitro susceptibilities of 393 recent clinical isolates to WIN 49375, a new quinolone derivative, were determined and concurrently tested with cefotaxime, tobramycin, and piperacillin. In general, members of the family Enterobacteriaceae were not as susceptible to tobramycin and piperacillin as they were to WIN 49375. Methicillin-resistant and -susceptible Staphylococcus aureus were equally susceptible to WIN 49375.

Full text

PDF
379

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Forward K. R., Harding G. K., Gray G. J., Urias B. A., Ronald A. R. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains. Antimicrob Agents Chemother. 1983 Oct;24(4):602–604. doi: 10.1128/aac.24.4.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fu K. P., Neu H. C. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978 Mar;13(3):358–367. doi: 10.1128/aac.13.3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Jones R. N., Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S300–S315. doi: 10.1093/clinids/4.supplement_2.s300. [DOI] [PubMed] [Google Scholar]
  4. Karakusis P. H., Feczko J. M., Goodman L. J., Hanlon D. M., Harris A. A., Levin S., Trenholme G. M. Clinical efficacy of cefotaxime in serious infections. Antimicrob Agents Chemother. 1982 Jan;21(1):119–124. doi: 10.1128/aac.21.1.119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Muytjens H. L., van der Ros-van de Repe J., van Veldhuizen G. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid. Antimicrob Agents Chemother. 1983 Aug;24(2):302–304. doi: 10.1128/aac.24.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Winston D. J., Wang D., Young L. S., Martin W. J., Hewitt W. L. In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother. 1978 Jun;13(6):944–950. doi: 10.1128/aac.13.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES